CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 138 filers reported holding CATALYST PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.04 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $409 | -59.1% | 22 | -77.3% | 0.00% | – |
Q3 2022 | $1,000 | -99.0% | 97 | -99.5% | 0.00% | -100.0% |
Q3 2021 | $99,000 | -7.5% | 18,581 | 0.0% | 0.01% | 0.0% |
Q2 2021 | $107,000 | +25.9% | 18,581 | 0.0% | 0.01% | +25.0% |
Q1 2021 | $85,000 | +54.5% | 18,581 | -0.0% | 0.00% | 0.0% |
Q3 2020 | $55,000 | -36.0% | 18,582 | 0.0% | 0.00% | -33.3% |
Q2 2020 | $86,000 | +65.4% | 18,582 | +35.2% | 0.01% | +50.0% |
Q1 2020 | $52,000 | +108.0% | 13,747 | +111.8% | 0.00% | +100.0% |
Q4 2019 | $25,000 | +31.6% | 6,492 | +91.4% | 0.00% | +100.0% |
Q3 2019 | $19,000 | -62.0% | 3,392 | -74.4% | 0.00% | -66.7% |
Q2 2019 | $50,000 | +455.6% | 13,251 | +678.1% | 0.00% | +200.0% |
Q1 2019 | $9,000 | -86.6% | 1,703 | -95.0% | 0.00% | -83.3% |
Q4 2018 | $67,000 | +45.7% | 34,237 | +185.1% | 0.01% | +100.0% |
Q3 2018 | $46,000 | -99.9% | 12,010 | -27.3% | 0.00% | -25.0% |
Q2 2018 | $51,519,000 | +1030280.0% | 16,512 | +614.2% | 0.00% | – |
Q1 2018 | $5,000 | +66.7% | 2,312 | +125.3% | 0.00% | – |
Q4 2017 | $3,000 | – | 1,026 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TANAKA CAPITAL MANAGEMENT INC | 589,883 | $590,000 | 1.38% |
Broadfin Capital, LLC | 8,200,000 | $8,610,000 | 0.96% |
Avoro Capital Advisors LLC | 1,141,149 | $1,198,000 | 0.24% |
CORRADO ADVISORS, LLC | 190,600 | $200,000 | 0.12% |
Baker Brothers Advisors | 5,102,153 | $5,357,000 | 0.05% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 756,311 | $794,000 | 0.04% |
Point72 Asset Management, L.P. | 2,272,816 | $2,386,000 | 0.02% |
AGRAN LIBBIE | 44,000 | $46,000 | 0.01% |
COMPTON CAPITAL MANAGEMENT INC /RI | 10,000 | $11,000 | 0.01% |
KENNEDY CAPITAL MANAGEMENT LLC | 233,171 | $245,000 | 0.00% |